Spectrum Pharmaceuticals Q1 EPS $(0.02) Beats $(0.07) Estimate, Sales $15.62M Beat $10.50M Estimate; Acquisition By Assertio To Be Concluded By Q3 2023

Spectrum Pharmaceuticals (NASDAQ:SPPI) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.07) by 71.43 percent. This is a 77.78 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $15.62 million which beat the analyst consensus estimate of $10.50 million by 48.71 percent.